Skip to content

Reactive balance training to improve balance control and reduce falls in older adults: a randomized controlled trial.

Reactive balance training to improve balance control and reduce falls in older adults: a randomized controlled trial. - Reactive balance training in older adults

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON55445
Enrollment
80
Registered
2019-02-14
Start date
2019-03-27
Completion date
Unknown
Last updated
2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Verminderde balans bij het ouder worden decreased balance control impaired balance control

Interventions

Usual care physical therapy with (N=40) or without (N=40) three sessions of reactive balance training in a Computer Assisted Rehabilitation Environment.

Sponsors

Medisch Universitair Ziekenhuis Maastricht
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Age 65 or older. Community-dwelling. Able to walk independently without a walking aid for >15 minutes. Recently experienced a fall.

Exclusion criteria

Exclusion criteria: Diagnosed with osteoporosis. Any disease or disorder that may influence the safety of training (e.g. uncontrolled cardiopulmonary disease). Recent fracture or severe contusion of the lower extremities, back or shoulders. Falls caused by third parties or during sports activities. Uncorrected vision problems, history of syncope, use of medication known to increase fall risk or high doses of painkillers.

Design outcomes

Primary

MeasureTime frame
The main study parameter is balance control measured with the mini BESTest.

Secondary

MeasureTime frame
Secondary study parameters are prospective falls incidence measured with falls diaries until six months after the intervention, acceptability of the intervention, and fear of falling measured with the FES-I.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)